Regeneron Sinks After Late-Stage Melanoma Trial Failure
Regeneron Pharmaceuticals Inc. said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. The shares plunged in premarket trading.
By Naomi Kresge · Bloomberg
Regeneron Pharmaceuticals Inc. said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. The shares plunged in premarket trading.